A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma


Rochester, Minn., Jacksonville, Fla.

Trial status:

Open for Enrollment

Why is this study being done?

Pazopanib is an oral inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor VEGFR-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. Pazopanib is approved for the treatment of advanced soft tissue sarcoma, following progression on one prior systemic therapy, based on improved progression free survival. TRC105 is an antibody to CD105, an important angiogenic target on vascular endothelial cells that is distinct from VEGFR. TRC105 inhibits angiogenesis, tumor growth and metastases in preclinical models and complements the activity of bevacizumab and multi-kinase inhibitors that target the VEGFR. In a phase 1 study of advanced solid tumors, TRC105 therapy caused a global reduction in angiogenic biomarkers and reduced tumor burden at doses that were well-tolerated. In a phase 1b study, the combination of TRC105 and bevacizumab produced radiographic reductions in tumor volume in bevacizumab-refractory patients, and was well tolerated. TRC105 potentiates bevacizumab and VEGFR tyrosine kinases (VEGFR TKI) in preclinical models. By targeting a non-VEGF pathway that is upregulated following VEGF inhibition, TRC105 has the potential to complement VEGFR TKIs and could represent a major advance in cancer therapy. Together, the use of TRC105 with pazopanib may result in more effective angiogenesis inhibition and improved clinical efficacy over that seen with pazopanib alone.

Who is eligible to participate?

Inclusion Criteria: 1. Histologically confirmed unresectable soft tissue sarcoma (i.e., non-GIST, non-adipocytic)that has progressed following treatment with chemotherapy. Prior pazopanib is allowed if the drug was not discontinued for toxicity. 2. Measurable disease by RECIST 3. Age of 18 years or older 4. ECOG performance status ≤ 1 5. Resolution of all acute adverse events resulting from prior cancer therapies to NCI CTCAE grade ≤ 1 or baseline (except alopecia) 6. Adequate organ function 7. Willingness and ability to consent for self and to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures 8. Available archival tumor specimen of the soft tissue sarcoma that meets inclusion criterion #1. Exclusion Criteria: 1. Prior treatment with TRC105 2. Current treatment on another therapeutic clinical trial 3. Receipt of a small molecule anticancer agent, including an investigational anticancer small molecule, within 14 days of starting study treatment- 4. Receipt of a large molecule anticancer agent (e.g., antibody), including an investigational anticancer antibody, within 28 days of starting study treatment 5. Prior surgery (including open biopsy) within 28 days of starting the study treatment or the anticipated need for a major surgical procedure within the next six months 6. Prior radiation therapy within 28 days of starting the study treatment, except radiation therapy for bone metastases is permitted up to 14 days of starting treatment 7. Minor surgical procedures such as fine needle aspiration, Mediport placement or core biopsy within 7 days of study treatment 8. Uncontrolled chronic hypertension defined as systolic > 150 or diastolic > 90 despite optimal therapy (initiation or adjustment of BP medication prior to study entry is allowed provided that the average of 3 BP readings at a visit prior to enrollment is < 140/90 mm Hg) 9. Symptomatic ascites or pericardial or pleural effusion 10. History of brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for at least 30 days. 11. Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, Venous thrombosis, including pulmonary embolism and deep venous thrombosis (unless adequately anticoagulated without warfarin for more than two weeks), PTCA or CABG within the past 6 months 12. Active bleeding or pathologic condition that carries a high risk of bleeding (e.g. hereditary hemorrhagic telangiectasia). Patients who have been uneventfully anti-coagulated with low molecular weight heparin are eligible. 13. Thrombolytic use (except to maintain i.v. catheters) within 10 days prior to first day of study therapy 14. Cardiac dysrhythmias of NCI CTCAE grade ≥ 2 within the last 28 days 15. Known active viral or nonviral hepatitis or cirrhosis 16. History of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 6 months of starting study treatment 17. History of peptic ulcer disease or erosive gastritis within the past 6 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD)within 28 days of starting study treatment 18. History of gastrointestinal perforation or fistula in the past 6 months, or while previously on antiangiogenic therapy, unless underlying risk has been resolved (e.g., through surgical resection or repair) 19. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)related illness 20. Pregnancy or breastfeeding.

Last updated:




IRB Number: